Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR). There is paucity of information regarding non‐Aspergillus invasive mould infections (NAIMIs) in this setting,

中文翻译：

---

依鲁替尼治疗患者的非曲霉侵袭性霉菌感染

侵袭性霉菌感染 (IMI) 在淋巴恶性肿瘤患者中非常罕见。然而，在接受依鲁替尼 (IBR) 治疗的此类患者中，越来越多地报道了 IMI，主要是曲霉属物种所致。在这种情况下，关于非曲霉菌侵袭性霉菌感染 (NAIMI) 的信息很少，